TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

KAPSPARGO SPRINKLE

METOPROLOL SUCCINATE
Cardiovascular Approved 2018-01-26
Jump to: Indications Approvals Trials Competitors Similar Safety Patents
1
Indication
--
Phase 3 Trials
8
Years on Market

Details

Status
Prescription
First Approved
2018-01-26
Routes
ORAL
Dosage Forms
CAPSULE, EXTENDED RELEASE

Companies

SPIL
Active Ingredient: METOPROLOL SUCCINATE

KAPSPARGO SPRINKLE Approval History

Loading approval history...

What KAPSPARGO SPRINKLE Treats

3 indications

KAPSPARGO SPRINKLE is approved for 3 conditions since its original approval in 2018. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hypertension
  • Angina Pectoris
  • Heart Failure
Source: FDA Label

Drugs Similar to KAPSPARGO SPRINKLE

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

TOPROL-XL
METOPROLOL SUCCINATE
3 shared
MELINTA THERAP
Shared indications:
HypertensionAngina PectorisHeart Failure
ALDACTONE
SPIRONOLACTONE
2 shared
Pfizer
Shared indications:
Heart FailureHypertension
ATACAND
CANDESARTAN CILEXETIL
2 shared
ANI PHARMS
Shared indications:
HypertensionHeart Failure
CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL
2 shared
MACLEODS PHARMS LTD
Shared indications:
HypertensionHeart Failure
CAROSPIR
SPIRONOLACTONE
2 shared
CMP DEV LLC
Shared indications:
Heart FailureHypertension
CARVEDILOL PHOSPHATE
CARVEDILOL PHOSPHATE
2 shared
Sun Pharma
Shared indications:
Heart FailureHypertension
COREG
CARVEDILOL
2 shared
WAYLIS THERAP
Shared indications:
Heart FailureHypertension
COREG CR
CARVEDILOL PHOSPHATE
2 shared
WAYLIS THERAP
Shared indications:
Heart FailureHypertension
DIOVAN
VALSARTAN
2 shared
Novartis
Shared indications:
HypertensionHeart Failure
ENALAPRIL MALEATE
ENALAPRIL MALEATE
2 shared
ALKEM LABS LTD
Shared indications:
HypertensionHeart Failure
EPANED
ENALAPRIL MALEATE
2 shared
AZURITY
Shared indications:
HypertensionHeart Failure
INDERAL LA
PROPRANOLOL HYDROCHLORIDE
2 shared
ANI PHARMS
Shared indications:
HypertensionAngina Pectoris
LISINOPRIL
LISINOPRIL
2 shared
Aurobindo Pharma
Shared indications:
HypertensionHeart Failure
NADOLOL
NADOLOL
2 shared
Aurobindo Pharma
Shared indications:
Angina PectorisHypertension
PROPRANOLOL HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE
2 shared
IPCA LABS LTD
Shared indications:
HypertensionAngina Pectoris
QBRELIS
LISINOPRIL
2 shared
AZURITY
Shared indications:
HypertensionHeart Failure
THALITONE
CHLORTHALIDONE
2 shared
CASPER PHARMA LLC
Shared indications:
HypertensionHeart Failure
TRANDOLAPRIL
TRANDOLAPRIL
2 shared
Lupin
Shared indications:
HypertensionHeart Failure
VASOTEC
ENALAPRIL MALEATE
2 shared
BAUSCH
Shared indications:
HypertensionHeart Failure
VOSTALLY
RAMIPRIL
2 shared
ROSEMONT PHARMS
Shared indications:
HypertensionHeart Failure
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

KAPSPARGO SPRINKLE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Metoprolol succinate, is a beta-adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. • Angina Pectoris. • Heart Failure, to reduce the risk of cardiovascular mortality and heart failure hospitalizations in patients with heart failure 1.1 Hypertension Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-...

KAPSPARGO SPRINKLE Patents & Exclusivity

Latest Patent: Jul 2035

Patents (32 active)

US9504655 Expires Jul 9, 2035
US9700530 Expires Jul 9, 2035
+ 22 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA210428 → Label: DailyMed → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.